Jonathan R Emberson

List of Publications by Year
in descending order

124 papers	50,928 citations	28190 55 h-index	16605 123 g-index
136 all docs	136 docs citations	136 times ranked	67844 citing authors

#	Article	IF	Citations
1	RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ: British Medical Journal, 2019, 366, l4898.	2.4	10,984
2	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	13.9	8,063
3	Body-mass index and cause-specific mortality in 900â€˜000 adults: collaborative analyses of 57 prospective studies. Lancet, The, 2009, 373, 1083-1096.	6.3	3,779
4	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, The, 2009, 373, 1849-1860.	6.3	3,100
5	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, The, 2016, 387, 957-967.	6.3	2,464
6	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
7	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	6.3	1,971
8	Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55â€˜000 vascular deaths. Lancet, The, 2007, 370, 1829-1839.	6.3	1,907
9	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1330.	3.8	1,855
10	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, The, 2016, 388, 2532-2561.	6.3	1,399
11	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174â€˜000 participants in 27 randomised trials. Lancet, The, 2015, 385, 1397-1405.	6.3	1,112
12	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	13.9	1,013
13	Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate. JAMA - Journal of the American Medical Association, 2012, 307, 1941-51.	3.8	810
14	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	2.6	609
15	A Randomized Controlled Trial of Exercise and Manipulative Therapy for Cervicogenic Headache. Spine, 2002, 27, 1835-1843.	1.0	593
16	Lopinavirâ€“ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	6.3	569
17	COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet, The, 2020, 396, 381-389.	6.3	521
18	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	6.3	512

#	Article	IF	Citations
19	Is the Association Between Parity and Coronary Heart Disease Due to Biological Effects of Pregnancy or Adverse Lifestyle Risk Factors Associated With Child-Rearing?. Circulation, 2003, 107, 1260-1264.	1.6	275
20	Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy. PLoS ONE, 2012, 7, e29849.	1.1	270
21	Perioperative Rosuvastatin in Cardiac Surgery. New England Journal of Medicine, 2016, 374, 1744-1753.	13.9	250
22	Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. The Lancet Gastroenterology and Hepatology, 2021, 6, 199-208.	3.7	244
23	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology,the, 2016, 4, 829-839.	5.5	234
24	Analyses of Cancer Data from Three Ezetimibe Trials. New England Journal of Medicine, 2008, 359, 1357-1366.	13.9	230
25	Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomised controlled trial. Lancet, The, 2001, 357, 509-512.	6.3	227
26	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. American Journal of Kidney Diseases, 2015, 66, 602-612.	2.1	210
27	Diabetes and Cause-Specific Mortality in Mexico City. New England Journal of Medicine, 2016, 375, 1961-1971.	13.9	207
28	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. Stroke, 2016, 47, 2373-2379.	1.0	193
29	Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. European Heart Journal, 2004, 25, 484-491.	1.0	190
30	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, The, 2016, 15, 925-933.	4.9	187
31	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology and Hepatology, 2018, 3, 231-241.	3.7	156
32	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20â€˜536 patients in the Heart Protection Study. Lancet, The, 2011, 377, 469-476.	6.3	154
33	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. American Journal of Kidney Diseases, 2010, 56, 1082-1094.	2.1	144
34	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	3.0	142
35	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. American Journal of Kidney Diseases, 2015, 66, 591-601.	2.1	138
36	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet, The, 2019, 393, 2613-2623.	6.3	134

#	Article	IF	Citations
37	Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science, 2021, 373, .	6.0	130
38	Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clinical Trials, 2008, 5, 49-55.	0.7	129
39	Statins for people at low risk of cardiovascular disease â€“ Authors' reply. Lancet, The, 2012, 380, 1817-1818.	6.3	127
40	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet, The, 2014, 384, 1684-1690.	6.3	124
41	Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ: British Medical Journal, 2011, 342, d1250-d1250.	2.4	120
42	Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. European Heart Journal, 2003, 24, 1719-1726.	1.0	105
43	N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study. Journal of the American College of Cardiology, 2007, 49, 311-319.	1.2	104
44	Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both?. Vascular Health and Risk Management, 2006, 2, 239-249.	1.0	85
45	Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19 000 men in the Whitehall study. BMJ: British Medical Journal, 2009, 339, b3513-b3513.	2.4	84
46	Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12 000 deaths. European Heart Journal, 2013, 34, 1365-1374.	1.0	83
47	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	0.8	82
48	Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Medicine, 2012, 9, e1001310.	3.9	78
49	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer, 2016, 16, 488.	1.1	78
50	A Multicenter, Randomized, Placeboâ€Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1437-1449.	2.9	77
51	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. PLoS ONE, 2011, 6, e25920.	1.1	70
52	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology, The, 2019, 18, 643-652.	4.9	68
53	Cholesterol Fractions and Apolipoproteins as Risk Factors for Heart Disease Mortality in Older Men. Archives of Internal Medicine, 2007, 167, 1373.	4.3	67
54	Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 125-134.	3.1	66

#	Article	IF	Citations
55	Social class differences in coronary heart disease in middle-aged British men: implications for prevention. International Journal of Epidemiology, 2004, 33, 289-296.	0.9	58
56	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	2.1	57
57	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2014, 64, 40-48.	2.1	55
58	Cohort Profile: The Mexico City Prospective Study. International Journal of Epidemiology, 2006, 35, 243-249.	0.9	53
59	Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. European Heart Journal, 2008, 29, 800-809.	1.0	51
60	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. BMJ, The, 2015, 350, h1088-h1088.	3.0	51
61	Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. Lancet Diabetes and Endocrinology,the, 2018, 6, 455-463.	5.5	50
62	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	0.7	49
63	The prevalence of chronic diseases and major disease risk factors at different ages among 150 000 men and women living in Mexico City: cross-sectional analyses of a prospective study. BMC Public Health, 2009, 9, 9.	1.2	44
64	Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. American Heart Journal, 2015, 169, 605-612.	1.2	44
65	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	2.1	42
66	Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. European Heart Journal, 2012, 33, 1571-1581.	1.0	41
67	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 546-552.	2.2	41
68	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 47-60.	2.2	41
69	Conventional and Genetic Evidence on the Association between Adiposity and CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 127-137.	3.0	39
70	Body Fat Distribution and Systolic Blood Pressure in 10,000 Adults with Wholeâ€Body Imaging: UK Biobank and Oxford BioBank. Obesity, 2019, 27, 1200-1206.	1.5	38
71	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36
72	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. International Journal of Stroke, 2018, 13, 175-189.	2.9	36

#	Article	IF	Citations
73	Serum Free Light Chains and the Risk of ESRD and Death in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2829-2837.	2.2	35
74	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163.	3.2	33
75	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
76	Adiposity and Blood Pressure in 110â€‰000 Mexican Adults. Hypertension, 2017, 69, 608-614.	1.3	31
77	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	1.3	30
78	Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1ÂYear: BESTâ€Ð (Biochemical Efficacy and Safety Trial of Vitamin D). Journal of the American Heart Association, 2017, 6, .	1.6	30
79	Association of childhood smoking and adult mortality: prospective study of 120â€ˆ000 Cuban adults. The Lancet Global Health, 2020, 8, e850-e857.	2.9	30
80	Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial. EBioMedicine, 2018, 31, 133-142.	2.7	29
81	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
82	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage. JAMA Neurology, 2021, 78, 1179.	4.5	25
83	A Practical Method of Measuring Glomerular Filtration Rate by Iohexol Clearance Using Dried Capillary Blood Spots. Nephron Clinical Practice, 2007, 106, c104-c112.	2.3	24
84	Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study. Lancet Public Health, The, 2019, 4, e107-e115.	4.7	24
85	Cohort Profile: The Korean Cancer Prevention Study-II (KCPS-II) Biobank. International Journal of Epidemiology, 2018, 47, 385-386f.	0.9	23
86	The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study. Family Practice, 2004, 21, 582-586.	0.8	22
87	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplantation Research, 2013, 2, 7.	1.5	21
88	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	1.2	21
89	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. Kidney International, 2018, 93, 1165-1174.	2.6	21
90	General and Abdominal Adiposity and Mortality in Mexico City. Annals of Internal Medicine, 2019, 171, 397.	2.0	21

#	Article	IF	Citations
91	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	2.2	19
92	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
93	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) â€“ results of a randomized controlled clinical trial. American Journal of Transplantation, 2018, 18, 1424-1434.	2.6	18
94	Text messaging in smoking cessation: the txt2stop trial. Lancet, The, 2011, 378, 6-7.	6.3	17
95	Childhood Smoking, Adult Cessation, and Cardiovascular Mortality: Prospective Study of 390Â000 US Adults. Journal of the American Heart Association, 2020, 9, e018431.	1.6	14
96	Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial. Maturitas, 2015, 80, 426-431.	1.0	13
97	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	2.6	13
98	Strategic Need for Large Prospective Studies in Different Populations. JAMA - Journal of the American Medical Association, 2020, 323, 309.	3.8	13
99	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. Mayo Clinic Proceedings, 2017, 92, 1671-1681.	1.4	12
100	Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality. JAMA Oncology, 2021, 7, 1901.	3.4	12
101	Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150Â000 adults. International Journal of Epidemiology, 2021, 50, 955-964.	0.9	11
102	The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error. Journal of Clinical Epidemiology, 2004, 57, 1244-1252.	2.4	10
103	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2828-2839.	1.8	10
104	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. International Journal of Obesity, 2020, 44, 2256-2266.	1.6	9
105	Alcohol consumption and cause-specific mortality in Cuba: prospective study of 120 623 adults. EClinicalMedicine, 2021, 33, 100692.	3.2	9
106	Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150Â000 Mexican adults. European Journal of Preventive Cardiology, 2022, 29, 730-738.	0.8	8
107	Are statins useful in patients with advanced chronic kidney disease? â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2016, 4, 971-972.	5.5	7
108	INTERHEART. Lancet, The, 2005, 365, 117.	6.3	6

#	Article	IF	Citations
109	Stratification for exploring heterogeneity in systematic reviews. Evidence-Based Medicine, 2009, 14, 162-164.	0.6	6
110	Efficacy and safety of more intensive lowering of LDL cholesterol â€“ Authors' reply. Lancet, The, 2011, 377, 715-716.	6.3	6
111	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.4	6
112	Cohort Profile: the Cuba Prospective Study. International Journal of Epidemiology, 2019, 48, 680-681e.	0.9	6
113	Association of Blood Pressure With Cause-Specific Mortality in Mexican Adults. JAMA Network Open, 2020, 3, e2018141.	2.8	6
114	Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998â€“2004 and 2015â€“2019. Diabetes Care, 2021, 44, 944-951.	4.3	6
115	C-reactive protein in the Heart Protection Study â€“ Authors' reply. Lancet, The, 2011, 377, 1918-1919.	6.3	5
116	Thrombolysis in acute stroke â€“ Authors' reply. Lancet, The, 2015, 385, 1396.	6.3	5
117	Hydroxychloroquine for COVID-19: Balancing contrasting claims. European Journal of Internal Medicine, 2020, 82, 25-26.	1.0	5
118	Body-mass index, blood pressure, diabetes and cardiovascular mortality in Cuba: prospective study of 146,556 participants. BMC Public Health, 2021, 21, 963.	1.2	5
119	Cholesterol, statins, and mortality â€“ Authors' reply. Lancet, The, 2008, 371, 1162-1163.	6.3	2
120	Body mass index and COVID-19 mortality: prospective study of 120â€Š000 Mexican adults. International Journal of Epidemiology, 2022, 51, 1698-1700.	0.9	2
121	Randomization is Essential for Progress in Transplant Medicine. Transplantation, 2008, 86, 26-27.	0.5	1
122	Benefits of lowering cholesterol in chronic kidney disease â€“ Authors' reply. Lancet, The, 2011, 378, 1377-1378.	6.3	1
123	Commentary: Over-correction for regression dilution bias? Not for blood pressure vs coronary heart disease. International Journal of Epidemiology, 2005, 34, 1368-1369.	0.9	0
124	Aspirin in the primary prevention of vascular disease â€“ ATT secretariat's reply. Lancet, The, 2009, 374, 879.	6.3	0